H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $180
Analysts Conflicted on These Healthcare Names: Spruce Biosciences (OtherSPRB), Cigna (CI) and Axsome Therapeutics (AXSM)
Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Axsome Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $180 From $200
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $153
Baird Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $162
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Strong Buy Rating for Axsome Therapeutics Driven by Product Performance and Pipeline Progress
New Analyst Forecast: $AXSM Given 'Overweight' Rating
Express News | Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $165
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $176 to $210
Express News | Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $162
Axsome Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), TG Therapeutics (TGTX) and Vertex Pharmaceuticals (VRTX)
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $190 From $187, Maintains Buy Rating
Express News | Axsome Therapeutics Inc : BofA Global Research Raises Price Objective to $176 From $174
Axsome Therapeutics: Strong Growth Potential With Auvelity's Market Expansion and Strategic Initiatives
Axsome Therapeutics' Earnings Call Highlights Growth and Challenges
Axsome Therapeutics | 10-Q: Q1 2025 Earnings Report
Earnings Call Summary | Axsome Therapeutics(AXSM.US) Q1 2025 Earnings Conference